Skip to main content
    S

    Sutro Biopharma (STRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.92
    -0.40 (-4.29%)

    Market Cap: $154.72M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Sutro Biopharma (STRO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Sutro Biopharma (STRO) has a market cap of $154.72M and an enterprise value of $107.87M. Its share count is up 94.17% from a year earlier. It kept -344.22% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 30.28% below the market cap, as cash exceeds debt.

    Market Cap$154.72M
    Enterprise Value$107.87M
    Latest price (Nov 17, 2026)$8.92

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.07% in the quarter ended Sep 30, 2026 and shrank 55.04% a year over 2 years.

    Shares Outstanding16.58M
    Shares Change (YoY)+94.17%
    Shares Change (QoQ)+0.07%
    Share Count Growth (2Y CAGR)-55.04%

    Valuation Ratios

    The price to sales ratio is 3.3x. Its year-end P/S ranged from 1.0x to 6.0x from 2019 to 2025.

    P/S Ratio3.3x
    Forward P/S3.2x

    Price Statistics

    The stock is down 1.41% over 52 weeks and trades 30.09% below its 50-day average.

    Beta (1Y)1.54
    52-Week Change-1.41%
    1-Month Change-20.75%
    3-Month Change-59.29%
    6-Month Change-71.83%
    5-Year Change-95.49%
    Total Return (1Y)-1.41%
    Total Return (3Y CAGR)-30.78%
    Total Return (5Y CAGR)-45.25%
    Return vs SPY (1Y)-11.33%
    Max Drawdown (1Y)-78.32%
    Max Drawdown (3Y)-90.72%
    Sharpe Ratio (1Y)0.00
    Correlation with SPY (1Y)0.25
    50-Day Average$12.76
    200-Day Average$22.70
    52-Week Range$7.15 to $43.85
    RSI (14 Days)35.0
    Average Volume (20 Days)326.12K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.94x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio2.94x
    Quick Ratio2.94x
    Debt / Equity0.00x
    Interest Coverage-2.84x

    Returns and Efficiency

    Return on Assets (ROA)-87.90%
    Return on Capital Employed (ROCE)-97.72%
    ROA (5Y Average)-50.31%
    Asset Turnover0.23x
    Receivables Turnover4.85x

    Scores

    STRO has an Altman Z-Score of -9.59, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-9.59
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $45.11M over the last 12 months is down 57.30% from the 12 months before.

    Revenue$45.11M
    Revenue Growth (YoY)-57.30%
    Gross Profit$45.11M
    Operating Income-$119.55M
    Pretax Income-$155.36M
    Net Income-$155.27M
    EBITDA-$115.87M
    EBIT-$119.55M
    Reported EPS (TTM)-$12.62

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$46.85M
    Total Debt$0
    Net Cash$46.85M
    Net Cash Per Share$2.83
    Working Capital$105.19M
    Shareholder Equity-$132.54M
    Total Assets$176.65M
    Total Liabilities$309.18M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$129.44M
    FCF Per Share-$7.83
    Depreciation and Amortization$7.14M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -265.03%.

    Gross Margin100.00%
    Operating Margin-265.03%
    Pretax Margin-344.42%
    Net Margin-344.22%
    EBITDA Margin-256.88%
    EBIT Margin-265.03%

    Growth

    Revenue grew 14.78% a year over 3 years.

    Revenue Growth (3Y CAGR)+14.78%
    Revenue Growth (5Y CAGR)+19.12%

    Revenue and profit by year

    Dividends and Yields

    STRO does not pay a dividend.

    Buyback Yield-69.55%
    Shareholder Yield-69.55%

    Stock Splits

    The last split was a 1-for-10 reverse split on Dec 3, 2025.

    Last Split DateDec 3, 2025
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 4 similar companies, STRO has the lowest P/S.

    P/S Ratio3.3x vs 110.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)-57.30% vs -19.75% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -43.77% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-43.77%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About STRO

    What is STRO's market cap?

    Sutro Biopharma has a market cap of $154.72M. Its enterprise value, which adds debt and subtracts cash, is $107.87M.

    How many shares of STRO are outstanding?

    Sutro Biopharma has 16.58M shares outstanding. The count is up 94.17% from a year earlier.

    Does STRO pay a dividend?

    No. Sutro Biopharma does not pay a dividend.

    How much debt does STRO have?

    Sutro Biopharma has $0 of total debt and $46.85M of cash and equivalents, a net cash position of $46.85M.